137 patients with acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL) were given oral busulfan (Bu) 4 mg/kg on each of 4 days and intravenous cyclophosphamide (Cy) 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from an HLA-identical or one antigen disparate sibling.
data(leukemia)A data frame with 137 subjects on the following 22 variables.
GDisease Group (1=ALL, 2=AML Low Risk in first remission, 3=AML High Risk not in first remission)
TDTime To Death Or On Study Time
TBDisease Free Survival Time (Time To Relapse, Death Or End Of Study)
DDeath Indicator (0=Alive, 1=Dead)
RRelapse Indicator (0=Disease Free, 1=Relapsed)
BDisease Free Survival Indicator (0=Alive and Disease Free, 1=Dead or Relapsed)
TATime To Acute Graft-Versus-Host Disease (GVHD)
AAcute GVHD Indicator (0=Never Developed Acute GVHD, 1=Developed Acute GVHD)
TCTime To Chronic Graft-Versus-Host Disease (GVHD)
CChronic GVHD Indicator (0=Never Developed Chronic GVHD, 1=Developed Chronic GVHD)
TPTime of Platelets Returning to Normal Levels
PPlatelet Recovery Indicator (0=Platelets Never Returned to Normal, 1=Platelets Returned To Normal)
X1Patient Age In Years
X2Donor Age In Years
X3Patient Gender (0=female, 1=male)
X4Donor Gender (0=female, 1=male)
X5Patient Cytomegalovirus (CMV) Immune Status (0=CMV Negative, 1=CMV Positive)
X6Donor Cytomegalovirus (CMV) Immune Status (0=CMV Negative, 1=CMV Positive)
X7Waiting Time to Transplant In Days
X8AML Patients with Elevated Risk By French-American-British (FAB) Classification (0=Not AML/Elevated, 1=FAB M4 Or M5 with AML)
X9Hospital (1=The Ohio State University in Columbus, 2=Alfred in Melbourne, 3=St. Vincent in Sydney, 4=Hahnemann University in Philadelphia)
X10Methotrexate Used as a Graft-Versus-Host Disease Prophylactic (0=No, 1=Yes)
Copelan E., Biggs J., Thompson J., Crilley P., Szer J., Klein, J., Kapoor N., Avalos, B., Cunningham I. and Atkinson, K. (1991) "Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2". Blood, 78(3), pp.838-843.